NLRP3 and chronic kidney disease: As described previously, several drugs that target cytokines downstream of NLRP3 activation, e.g., anakinra and rilonacept, are currently being evaluated for the treatment of CKD; however, selective NLRP3 inhibitors, such as CY-09 and OLT1177 (dapansutrile) (344, 345), are still only undergoing preclinical testing (346, 347).